Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

TEVA – Teva Pharmaceutical Industries Limited

TEVA — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.5

Margin Of Safety %

-5

Put/Call OI Ratio

0.5

EPS Next Q Diff

EPS Last/This Y

-0.86

EPS This/Next Y

1.06

Price

43.65

Target Price

51.42

Analyst Recom

1.31

Performance Q

18.71

Upside

-66.3%

Beta

0.97

Ticker: TEVA




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-14TEVA40.740.520.10302508
2026-10-15TEVA41.120.520.05303457
2026-10-16TEVA41.490.520.03305605
2026-10-19TEVA41.290.500.15279530
2026-10-20TEVA40.860.500.84282739
2026-10-21TEVA40.620.490.44286865
2026-10-22TEVA40.20.490.11288504
2026-10-23TEVA39.40.490.39290907
2026-10-26TEVA39.970.510.10280881
2026-10-27TEVA40.30.500.03287801
2026-10-28TEVA39.990.501.49287954
2026-10-29TEVA41.470.500.09288655
2026-10-30TEVA42.080.490.13295299
2026-11-02TEVA40.60.490.54286845
2026-11-03TEVA41.90.510.32290842
2026-11-04TEVA41.820.510.93292409
2026-11-05TEVA41.770.521.58294862
2026-11-06TEVA42.610.520.61294463
2026-11-09TEVA42.980.500.98289057
2026-11-10TEVA42.390.511.24290612
2026-11-11TEVA43.210.510.50291915
2026-11-12TEVA43.660.500.81296066
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-14TEVA40.72- 1623.22.11
2026-10-15TEVA41.13- 1648.62.11
2026-10-16TEVA41.49- 1679.32.11
2026-10-19TEVA41.28- 1642.42.11
2026-10-20TEVA41.28- 1642.42.11
2026-10-21TEVA40.85- 1627.72.11
2026-10-22TEVA40.19- 1629.32.11
2026-10-23TEVA39.40- 1605.32.11
2026-10-26TEVA39.97- 1691.82.11
2026-10-27TEVA40.41- 1685.52.11
2026-10-28TEVA39.98- 1629.82.11
2026-10-29TEVA41.48- 1748.82.11
2026-10-30TEVA42.09- 1694.82.11
2026-11-02TEVA40.68- 1568.42.11
2026-11-04TEVA41.80- 2029.42.09
2026-11-05TEVA41.77- 2031.02.09
2026-11-06TEVA42.61- 2087.22.06
2026-11-09TEVA42.99- 2184.42.06
2026-11-10TEVA42.40- 2123.72.06
2026-11-11TEVA43.21- 2211.02.07
2026-11-12TEVA43.65- 2185.92.07
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-14TEVA-1.695.852.69
2026-10-15TEVA-1.695.852.69
2026-10-16TEVA-1.695.852.69
2026-10-19TEVA-1.696.062.69
2026-10-20TEVA-1.696.062.69
2026-10-21TEVA-1.696.062.69
2026-10-22TEVA-1.696.062.69
2026-10-23TEVA-1.696.062.69
2026-10-26TEVA-1.695.372.69
2026-10-27TEVA-1.695.372.53
2026-10-28TEVA-1.695.372.53
2026-10-29TEVA-1.695.372.53
2026-10-30TEVA-1.695.372.53
2026-11-02TEVA-1.695.542.53
2026-11-03TEVA-1.695.542.53
2026-11-05TEVA-1.415.542.53
2026-11-06TEVA-1.535.542.53
2026-11-09TEVA-1.468.622.53
2026-11-10TEVA-1.468.622.53
2026-11-11TEVA-1.468.622.50
2026-11-12TEVA-1.468.622.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

0.68

Avg. EPS Est. Next Quarter

0.63

Insider Transactions

-1.46

Institutional Transactions

8.62

Beta

0.97

Average Sales Estimate Current Quarter

4256

Average Sales Estimate Next Quarter

4068

Fair Value

41.45

Quality Score

74

Growth Score

55

Sentiment Score

93

Actual DrawDown %

-0.7

Max Drawdown 5-Year %

-43.7

Target Price

51.42

P/E

102.78

Forward P/E

14.01

PEG

2.31

P/S

2.95

P/B

6.38

P/Free Cash Flow

19.53

EPS

0.42

Average EPS Est. Cur. Y​

2.07

EPS Next Y. (Est.)

3.13

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

2.94

Relative Volume

1.56

Return on Equity vs Sector %

-20.1

Return on Equity vs Industry %

-0.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.08

EBIT Estimation

2185.9
◆ TEVA Healthcare
$43.65
📉
Swing / Pullback
Buy the dip on strong trends
49 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
3/15
Valuation
9/20
TP/AR
5/10
Options
6/10
RSI
65.7
Range 1M
89.1%
Sup Dist
2.2%
🚀
Momentum Growth
Ride accelerating trends
54 /100
WEAK
Momentum
21/25
Growth
10/30
Estimates
8/20
Inst/Vol
11/15
Options
4/10
EPS Yr
-29.8%
EPS NY
51.5%
52W%
97.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +77.6% upside
Quality
7/30
Valuation
16/30
Growth
8/25
Stability
1/10
LT Trend
4/5
Upside
+77.6%
Quality
74
MoS
-5%
TEVA — P/E HistoricalDrug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 31173
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
TEVA

Latest News

—
Caricamento notizie per TEVA…
stock quote shares TEVA – Teva Pharmaceutical Industries Limited Stock Price stock today
news today TEVA – Teva Pharmaceutical Industries Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TEVA – Teva Pharmaceutical Industries Limited yahoo finance google finance
stock history TEVA – Teva Pharmaceutical Industries Limited invest stock market
stock prices TEVA premarket after hours
ticker TEVA fair value insiders trading